Literature DB >> 15902285

A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.

A J Davies1, A M Lee, C Taylor, A J Clear, L K Goff, S Iqbal, D Cuthbert-Heavens, M Calaminici, A J Norton, T A Lister, J Fitzgibbon.   

Abstract

The role of TP53 mutation in transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (t-FL) was examined in a panel of 91 lymph node biopsies derived from 29 patients pre- and post-transformation. The entire TP53 coding sequence was screened and immunocytochemistry performed to determine expression of p53 and its key regulator MDM2. A total of 10 mutations were detected in eight patients (28%), although none were present at FL diagnosis. Mutations were not detected solely at the time of transformation; in three patients, mutated TP53 arose in at least one antecedent FL sample (6 months, 2.5 years and 4 years prior to transformation). Loss of heterozygosity at the TP53 locus occurred in 2/20 informative patients (only in t-FL samples). p53 staining was positive in 82% (9/11) of available biopsies with a missense mutation, and negative in 71% (45/63) with wtTP53. MDM2 expression was significantly higher in t-FL samples (mean 72% positive; 95% confidence interval (95% CI) 68-76%) than FL (mean 58% positive; 95% CI 54-62%) (P<0.001) but did not correlate with TP53 status. TP53 mutation has only a limited role in the transformation of FL, exerting a heterogeneous influence upon phenotypic change. In contrast, dysregulation of MDM2 is frequent and may provide a more rational therapeutic target.. Leukemia (2005) 19, 1459-1465.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902285     DOI: 10.1038/sj.leu.2403802

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

Review 1.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

2.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.

Authors:  Andrew J Davies; Andreas Rosenwald; George Wright; Abigail Lee; Kim W Last; Dennis D Weisenburger; Wing C Chan; Jan Delabie; Rita M Braziel; Elias Campo; Randy D Gascoyne; Elaine S Jaffe; Konrad Muller-Hermelink; German Ott; Maria Calaminici; Andrew J Norton; Lindsey K Goff; Jude Fitzgibbon; Louis M Staudt; T Andrew Lister
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

3.  Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.

Authors:  David Wrench; Rachel Waters; Emanuela Carlotti; Sameena Iqbal; Janet Matthews; Marie Calaminici; John Gribben; T Andrew Lister; Jude Fitzgibbon
Journal:  Haematologica       Date:  2008-11-23       Impact factor: 9.941

Review 4.  Pathogenesis of follicular lymphoma.

Authors:  Robert Kridel; Laurie H Sehn; Randy D Gascoyne
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 5.  Unmet needs in the first-line treatment of follicular lymphoma.

Authors:  C Casulo; L Nastoupil; N H Fowler; J W Friedberg; C R Flowers
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

6.  The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.

Authors:  Derville O'Shea; Ciarán O'Riain; Claire Taylor; Rachel Waters; Emanuela Carlotti; Finlay Macdougall; John Gribben; Andreas Rosenwald; German Ott; Lisa M Rimsza; Erlend B Smeland; Nathalie Johnson; Elias Campo; Timothy C Greiner; Wing C Chan; Randy D Gascoyne; George Wright; Louis M Staudt; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2008-07-15       Impact factor: 22.113

7.  Cell of origin of transformed follicular lymphoma.

Authors:  Robert Kridel; Anja Mottok; Pedro Farinha; Susana Ben-Neriah; Daisuke Ennishi; Yvonne Zheng; Elizabeth A Chavez; Hennady P Shulha; King Tan; Fong Chun Chan; Merrill Boyle; Barbara Meissner; Adele Telenius; Laurie H Sehn; Marco A Marra; Sohrab P Shah; Christian Steidl; Joseph M Connors; David W Scott; Randy D Gascoyne
Journal:  Blood       Date:  2015-08-25       Impact factor: 22.113

8.  p37Ing1b regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphomagenesis.

Authors:  Andrew H Coles; Concetta G A Marfella; Anthony N Imbalzano; Heather A Steinman; David S Garlick; Rachel M Gerstein; Stephen N Jones
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

9.  Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations.

Authors:  Hege Vangstein Aamot; Emina Emilia Torlakovic; Marianne Brodtkorb Eide; Harald Holte; Sverre Heim
Journal:  J Cancer Res Clin Oncol       Date:  2007-01-18       Impact factor: 4.322

10.  Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Authors:  E Drakos; R R Singh; G Z Rassidakis; E Schlette; J Li; F X Claret; R J Ford; F Vega; L J Medeiros
Journal:  Leukemia       Date:  2011-03-11       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.